Publications

Showing 3 of 3 Publications

2023

Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial
Tumati S, Vieira D, Bawa K, Andreazza A, Mintzer J, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Herrmann N, Lanctôt K. Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079161.
Peer-Reviewed Original Research
Concepts
Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.
Peer-Reviewed Original Research
MeSH Keywords and Concepts

2017

[O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS
Lanctot K, Scherer R, Li A, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J. [O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS. Alzheimer's & Dementia 2017, 13: p184-p184. DOI: 10.1016/j.jalz.2017.07.038.
Peer-Reviewed Original Research
Concepts

Download Full List